Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03640286Not ApplicableCompleted

Vestibular Stimulation to Trigger Adipose Loss (VeSTAL) Clinical Trial

Role: collaborator

NCT04433273Not ApplicableNot Yet Recruiting

Electrical Vestibular Stimulation (VeNS): Assessment of AMPK & SIRT1 Following Repeated Usage

Role: collaborator

NCT04149951Not ApplicableCompleted

Effect of VeSTAL Device in Type 2 Diabetes Mellitus

Role: collaborator

NCT04110717Not ApplicableCompleted

Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control as a Means of Reducing Excess Body Weight

Role: collaborator

NCT04219566Not ApplicableCompleted

Vestibular Nerve Stimulation to Improve Sleep

Role: collaborator

All 5 trials loaded